[Experience in clinical use of primalan (mequitazine) in allergology].

Abstract

AIM:

To study efficacy of primalan (mequitasine) in the treatment of allergic rhinoconjunctivitis and chronic recurrent urticaria.

MATERIAL AND METHODS:

The study included 140 patients. Of them, 60 patients had allergic rhinitis, 80 patients had chronic recurrent urticaria. All the patients received primalan (mequitasin) in a dose 10 mg/day (5 mg twice daily or a single dose 10 mg). The disease symptoms and side effects of primalan were assessed for 28 days of the treatment.

RESULTS:

Primalan (mequitasin) proved to be highly effective against allergic rhinitis (good and very good response--76%, satisfactory--20%) and chronic recurrent urticaria (the response in 90% patients). Good primalan tolerance was reported. Side effects were moderate and did not require the drug withdrawal (sleepiness in 6.6%, dryness of the mucosa in 5%).

CONCLUSION:

Primalan (mequitasin) can be recommended for wide application in therapy of allergic rhinitis and chronic recurrent urticaria.

• Authors: N I Il'ina, T V Latysheva, M I Varfolomeeva
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 75 Issue 4 Pg. 58-60 ( 2003) ISSN: 0040-3660 [Print] Russia (Federation)
• Vernacular Title: Opyt klinicheskogo primeneniia primalana (mekvitazina) v allergologii.
• PMID: 12793141 (Publication Type: English Abstract, Journal Article)

Chemical References

• Histamine H1 Antagonists
• Phenothiazines
• mequitazine

Topics

• Adolescent
• Adult
• Aged
• Child
• Female
• Histamine H1 Antagonists (adverse effects, therapeutic use)
• Humans
• Hypersensitivity (classification, drug therapy)
• Male
• Middle Aged
• Phenothiazines (adverse effects, therapeutic use)
• Treatment Outcome